Chronic Myelomonocytic Leukemia

Oncology
4
Pipeline Programs
4
Companies
4
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
150%
Small Molecule
150%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
CanakinumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT04239157Recruiting76Est. Dec 2026
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 program
1
OlutasidenibPhase 2Small Molecule1 trial
Active Trials
NCT06597734RecruitingEst. Aug 2029
Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
Decitabine and CedazuridinePhase 1/21 trial
Active Trials
NCT04655755Active Not Recruiting52Est. Jul 2026
Solu Therapeutics
1 program
1
STX-0712Phase 11 trial
Active Trials
NCT06950034RecruitingEst. Jun 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Rigel PharmaceuticalsOlutasidenib
NovartisCanakinumab
Astex PharmaceuticalsDecitabine and Cedazuridine
Solu TherapeuticsSTX-0712

Clinical Trials (4)

Total enrollment: 128 patients across 4 trials

NCT06597734Rigel PharmaceuticalsOlutasidenib

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

Start: Jan 2025Est. completion: Aug 2029
Phase 2Recruiting
NCT04239157NovartisCanakinumab

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Start: Aug 2020Est. completion: Dec 202676 patients
Phase 2Recruiting
NCT04655755Astex PharmaceuticalsDecitabine and Cedazuridine

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Start: Jan 2021Est. completion: Jul 202652 patients
Phase 1/2Active Not Recruiting
NCT06950034Solu TherapeuticsSTX-0712

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Start: Mar 2025Est. completion: Jun 2027
Phase 1Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 128 patients
4 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)